Aarti Drugs hit a lower circuit of 10% at Rs 2936.90, extending its losing streak to second trading session.Shares of Aarti Drugs have lost 14.5% in two trading days from its previous closing high of Rs 3,435 on 24 August 2020.
The counter witnessed profit booking after its recent rally. In last one month, the stock has rallied 85% compared with 2.48% rise in benchmark BSE Sensex.
The stock has soared 595.5% from its 52-week low of Rs 422.25 on 19 March 2020. The counter hit an all time high of Rs 3,724.50 on Tuesday (25 August).
On the technical front, the stock's RSI (relative strength index) stood at 67.40. The RSI oscillates between zero and 100. Traditionally the RSI is considered overbought when above 70 and oversold when below 30.
The stock is currently trading above its 50-day, 100-day and 200-day simple moving averages placed at 1753.78, 1278.27 and 924.58 respectively.
Aarti Drugs is a pharmaceutical company. The company has a strong presence in the anti-diarrhea, anti-inflammatory therapeutic groups.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.